Coal worker's pneumoconiosis
Coal worker's pneumoconiosis is a lung disease that results from breathing in dust from coal, graphite, or man-made carbon over a long time.
Black lung disease; Pneumoconiosis; Anthrosilicosis
Coal worker's pneumoconiosis occurs in two forms: simple and complicated (also called progressive massive fibrosis, or PMF).
Your risk of developing coal worker's pneumoconiosis depends on how long you have been around coal dust. Most people with this disease are older than 50. Smoking does not increase your risk of developing this disease, but it may have an added harmful effect on the lungs.
Symptoms of this condition include:
Exams and Tests
Treatment may include any of the following, depending on how severe your symptoms are:
- Medicines to keep the airways open and reduce mucus
- Pulmonary rehabilitation to help you learn ways to breathe better
- Oxygen therapy
Ask your health care provider about Black Lung Clinics in your area. Information can be found at the National Coalition of Black Lung and Respiratory Disease Clinics website: blacklungcoalition.org/clinics.
Outcome for the simple form is usually good. It rarely causes disability or death. The complicated form may cause shortness of breath that worsens over time.
Complications may include:
- Chronic bronchitis
- Chronic obstructive pulmonary disease (COPD)
- Cor pulmonale (failure of the right side of the heart)
- Respiratory failure
Wear a protective mask when working around coal, graphite, or man-made carbon. Companies should enforce the maximum permitted dust levels. Avoid smoking.
Cowie RL, Becklake MR. Pneumoconioses. In: Broaddus VC, Mason RJ, Ernst JD, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 6th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 73.
Tarlo SM. Occupational lung disease. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 93.
Reviewed By: Denis Hadjiliadis, MD, MHS, Associate Professor of Medicine, Pulmonary, Allergy, and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.